Drug manufacturer GlaxoSmithKline for the third time this year has announced refunds for overcharging 340B covered entities, this time for purchases of 16 NDCs during Q3 2020.
The U.S. Health Resources and Services Administration (HRSA) posted GSK’s notice to entities yesterday
…